Antibiotics

Antibiotics
Mupirocin [HOT]
4-AA [Intermediate] [HOT]

 

 

Amikacin Sulfate,39831-55-5/149022-22-0
Amikacin Sulfate(1:2)
Amikacin Sulfate,39831-55-5/149022-22-0
CAS
39831-55-5/149022-220
Molecular Formula
C22H43N5O13.2H2O4S
Molecular Weight
781.759
Systematic Name
Amikacin bis(sulphate)
Standard
USP35,GMP
Certificate of analysis
Amikacin Sulfate,39831-55-5/149022-22-0
View via PDF file
Amikacin Sulfate,39831-55-5/149022-22-0
Specification
Items
Specification
Test result
Appearance
White, crystalline powder
White crystalline powder
Solubility
freely soluble in water
Complies
Specific rotation(dry)
+76°to +84°
+78°
pH(25℃)
2.0 to 4.0
3.7
Identification
Meet the requirement
Complies
Loss on drying
Not more than 13.0%
8.1%
Crystallinity
Meet the requirement
Complies
Reside on ignition
Not more than 1.0%
0.11%
Bacterial endotoxins
Not more than 0.25EU/mg
Complies
Assay(Dried basis)
674μ to 786μ/mg
734μ/mg
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Antibiotics
Mupirocin [HOT]
4-AA [Intermediate]
 
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Amikacin Sulfate,39831-55-5).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.